Nanologix is a biotechnology company focused on sale of Petri plates packaged in an exclusive licensed Flatpack and the N-Assay rapid detection technology for bacteria, mold, and spores.
NanoLogix technology is used to test for bacteria and other microorganisms and in some cases, dependent upon the technology used, provide for early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories.
NanoLogix began 26 years ago under the name Infectech. From its founding through 2007 the Company had been issued patents that were in some cases practically, and in other cases theoretically, applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, pharmacology, pharmaco-kinetics, and determination of antibiotic sensitivity.
In 2007, with a management change, the focus of the company changed from Research and Development to exploring how to capitalize on the company's existing intellectual property. It became obvious that the patents of the past possessed little monetary value for the future and that realization resulted in a further change in direction seeking to focus on practicality in research and a focus on a long term future return for the company and its shareholders. The period from 2007 through 2011 resulted in the abandonment of any focus on the production of hydrogen through bacteria degradation of organic waste utilizing what was referred to as a "bioreactor". The reason for the abandonment of the technology was the discovery of a lack of evidence for any economic potential for the technology. A similar discovery led to the practical abandonment of the NanoLogix BNC (BioNanoChannel) technology. While potentially a novel approach to diagnostics, major-lab third-party tests and a subsequent economic analysis demonstrated that under no conditions could the cost of both the antibody coating and specialized glass microchannel disc contained in the apparatus be reduced to a level to enable effective marketing. Over the following year, NanoLogix went through a transition to production of FlatPack™ Petri plates and BNP™ diagnostic test kits. Sales of both began in Q3 2012.
NanoLogix' rapid diagnostic technology is the N-Assay modified ELISA diagnostic.
NanoLogix N-Assay technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), Nanologix technology does not require large investments in equipment or personnel training.
Rapid diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process, and furnishes the follwing as benefits:
Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention.
In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process.
Industrial production - of food, beverage, drugs, or beauty products - can be paralyzed by microbial contamination. The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product. Rapid diagnostics can help minimize the impact by limiting the spread of spoiled product.
The volume of Petri dishes used for traditional tests is millions per day worldwide.
According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.
NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions.
NanoLogix's research and development continues on other diagnostic technology with variants in the N-Assay currently being developed for one of the world's largest Medical Device companies.
http://dx.doi.org/10.1155/2016/5293034 Infectious Diseases in Obstetrics and Gynecology Volume 2016 (2016), Article ID 5293034, 7 pages
Development of a Novel Test for Simultaneous Bacterial Identification and Antibiotic Susceptibility
1The Woman’s Hospital of Texas, 7400 Fannin Suite 930, Houston, TX 77054, USA
2The University of Texas Health Science Center at Houston, Medical College, Houston, TX 77054, USA
Received 13 May 2016; Accepted 10 August 2016
Academic Editor: Bryan Larsen
Copyright © 2016 Jonathan Faro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Elucidation of a pathogen’s antimicrobial susceptibility requires subculture after the organism is first isolated. This takes several days, requiring patients to be treated with broad-spectrum antibiotics. This approach contributes to the development of bacterial resistance. Methods. Microtiter wells were coated with a polyclonal antibody targeting the pathogen of interest. Bacterial suspensions were added in the presence/absence of selected antibiotics. After washing, captured bacteria were detected. Findings. Group B streptococcus (GBS), Enterococcus faecalis, and Neisseria gonorrhoeae were each detected at 105 bacteria/mL following a 20-minute incubation period. Susceptibility to select antibiotics was discernable following a 6-hour incubation period (GBS and Enterococcus). Sensitivity was increased to 10−2 bacteria/mL for GBS, 10−1 bacteria/mL for E. faecalis, and 101 bacteria/mL for N. gonorrhoeae following 18–24-hour culture. Conclusion. This novel assay allows for the highly sensitive and specific identification of a pathogen and simultaneous determination of its antimicrobial susceptibility in a reduced time.
Estimated Market Cap
- $8,410,892 as of December 31, 2015
As of 31 December 2015, the company has 140,181,530 shares outstanding. Outstanding on 12/31/14 were 139,531,530 shares.
Authorized Shares 200,000,000 as of Dec 31, 2015
Number of Share Holders of Record
- 2,000+/- shareholders as of end of 2015.
Float of 109,522,269 shares as of Dec 31, 2015
( 1 month daily, 3 month daily, 1 year weekly)
843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 main line
E-mail: [email protected]
Web site questions:
E-mail: [email protected]
NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.
The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.
Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.
NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity..